ORIC Pharmaceuticals rakes in $53 mln Series B

By Iris Dorbian — 2 months ago

South San Francisco-based cancer therapy company ORIC Pharmaceuticals has secured $53 million in Series B funding. The investors included The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. In addition to the funding, Dr. Carl L. Gordon of OrbiMed and Dr. Leo A. Guthart of Topspin have been appointed to ORIC’s board.

Continue

VC-backed ProNAi files for IPO

By Iris Dorbian — 8 months ago

Vancouver-based ProNAi Therapeutics, a developer of nucleic acid therapeutics, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The stock will list on the NASDAQ under the ticker symbol “DNAI.” Jefferies LLC and BofA Merrill Lynch will serve as the lead underwriters. ProNAi’s backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue

VC-backed Glaukos Corp files for IPO

By Iris Dorbian — 9 months ago

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

Continue

Natera reels in about $55.5 mln

By Iris Dorbian — 10 months ago

San Carlos, California-based Natera Inc, a provider of non-invasive genetic testing, has secured about $55.5 million in funding. Sofinnova Ventures led the round with participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors. In conjunction with the funding, Dr James Healy, a general partner at Sofinnova, has been appointed to Natera’s board of directors.

Continue

Selecta Biosciences raises $20 million

By Luisa Beltran — 1 year ago

Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.

Continue

Sonendo raises $35 mln equity financing

By Luisa Beltran — 1 year ago

Sonendo said Monday it completed an equity financing round of $35 million led by Meritech Capital Partners. New investor SEB Private Equity joined Fjord Ventures, OrbiMed Advisors and NeoMed Management in the round. Laguna Hills, Calif.-based Sonendo develops technology for the root canal therapy market.

Continue

Civitas Therapeutics scores $55 mln Series C

By Iris Dorbian — 1 year ago

Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Canaan Partners, RA Capital and Wellington Management Company. Headquartered in Chelsea, Mass., Civitas Therapeutics is a biopharmaceutical company that focuses on developing treatments for Parkinson’s disease.

Continue

NEA leads Series B round for Loxo Oncology

By Iris Dorbian — 2 years ago

Loxo Oncology has received $24 million in Series B financing. New Enterprise Associates led the round with participation from previous backers Aisling Capital and OrbiMed Advisors. In addition to the funding, Dr. M. James Barrett, a general partner at NEA, will join Loxo Oncology’s board of directors while Dr. Sara Nayeem, a principal at NEA, will also join the board as an observer. And, the firm has named Dr. Mikel Moyer as chief scientific officer. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.

Continue

Otonomy scores $49 mln Series D funds

By Iris Dorbian — 2 years ago

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

Continue

ProNAi Therapeutics raises Series D

By Angela Sormani — 2 years ago

ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue